DZ Bank’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

DZ Bank’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-769	Closed	-$227K	–	1119
2018 Q1	$227K	Buy	+769	New	+$227K	﹤0.01%	915

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DZ Bank's EIGR Position: Q2 2018 in Review

DZ Bank sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2018, closing a stake of 769 shares — an estimated $227K sold.

DZ Bank first reported a position in EIGR in Q1 2018 and held it in 1 quarter. The position peaked at $227K in Q1 2018. 50 funds tracked by Wall St. Rank hold EIGR as of Q2 2018.

DZ Bank reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 769 Eiger BioPharmaceuticals, Inc. shares in Q2 2018, an estimated $227K.
DZ Bank first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
DZ Bank's Eiger BioPharmaceuticals, Inc. position peaked at $227K in Q1 2018.
50 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.